NASDAQ:APEN - Apollo Endosurgery Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apollo Endosurgery Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.75 0.00 (0.00 %) (As of 02/25/2020 01:26 PM ET) Add Compare Today's Range$2.70Now: $2.75▼$2.7050-Day Range$2.70MA: $2.94▼$3.2052-Week Range$2.50Now: $2.75▼$4.08Volume180 shsAverage Volume12,297 shsMarket Capitalization$57.60 millionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APEN Previous Symbol CUSIPN/A CIK1251769 Webhttp://www.apolloendo.com/ Phone512-279-5100Debt Debt-to-Equity Ratio5.31 Current Ratio2.86 Quick Ratio2.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.85 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book2.08Profitability EPS (Most Recent Fiscal Year)($1.92) Net Income$-45,790,000.00 Net Margins-71.59% Return on Equity-176.86% Return on Assets-46.15%Miscellaneous Employees215 Outstanding Shares20,944,000Market Cap$57.60 million Next Earnings Date3/16/2020 (Estimated) OptionableNot Optionable Receive APEN News and Ratings via Email Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:APEN Rates by TradingView Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions What is Apollo Endosurgery's stock symbol? Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN." How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery Inc (NASDAQ:APEN) released its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.02. The biotechnology company earned $11.26 million during the quarter, compared to the consensus estimate of $13.37 million. Apollo Endosurgery had a negative return on equity of 176.86% and a negative net margin of 71.59%. View Apollo Endosurgery's Earnings History. When is Apollo Endosurgery's next earnings date? Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Apollo Endosurgery. Has Apollo Endosurgery been receiving favorable news coverage? News articles about APEN stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Apollo Endosurgery. Who are some of Apollo Endosurgery's key competitors? Some companies that are related to Apollo Endosurgery include iCAD (ICAD), Cytosorbents (CTSO), Soliton (SOLY), TELA Bio (TELA), Vapotherm (VAPO), RenovaCare (RCAR), Pulse Biosciences (PLSE), Liquidia Technologies (LQDA), BRAINSWAY LTD/S (BWAY), PAVmed (PAVM), Spectral Medical (EDTXF), BeyondAirInc . (XAIR), SANUWAVE Health (SNWV), AIT Therapeutics (AITB) and Pro-Dex (PDEX). What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Onconova Therapeutics (ONTX), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE). Who are Apollo Endosurgery's key executives? Apollo Endosurgery's management team includes the folowing people: Mr. Todd Newton, CEO & Director (Age 56)Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation PartnerMr. Anthony Kalloo M.D., Co-Founder and Innovation PartnerDr. Robert Hawes M.D., Co-Founder and Innovation PartnerDr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner Who are Apollo Endosurgery's major shareholders? Apollo Endosurgery's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (4.77%), Renaissance Technologies LLC (0.41%), Russell Investments Group Ltd. (0.36%) and University of Texas Texas AM Investment Managment Co. (0.07%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Institutional Ownership Trends for Apollo Endosurgery. Which major investors are selling Apollo Endosurgery stock? APEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View Insider Buying and Selling for Apollo Endosurgery. Which major investors are buying Apollo Endosurgery stock? APEN stock was purchased by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, University of Texas Texas AM Investment Managment Co. and Renaissance Technologies LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Insider Buying and Selling for Apollo Endosurgery. How do I buy shares of Apollo Endosurgery? Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Apollo Endosurgery's stock price today? One share of APEN stock can currently be purchased for approximately $2.75. How big of a company is Apollo Endosurgery? Apollo Endosurgery has a market capitalization of $57.60 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.View Additional Information About Apollo Endosurgery. What is Apollo Endosurgery's official website? The official website for Apollo Endosurgery is http://www.apolloendo.com/. How can I contact Apollo Endosurgery? Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected] MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 208 (Vote Outperform)Underperform Votes: 179 (Vote Underperform)Total Votes: 387MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: How does a security become overbought?
